For example, higher c‐met levels are associated with poor response and outcome in myeloma patients treated with BTZ‐based therapies.11 Knockdown of c‐met by shRNA in vitro increases sensitivity to BTZ in MM U266 cells.34 Furthermore, SU11274, a novel selective c‐met inhibitor, is known to induce apoptosis and necrosis, and it can reverse BTZ resistance in R5 cells.27 Our results suggest that SL1 is comparable to other BTZ‐based combination treatments for MM. Here, CASC3 is linked to plasma cell myeloma.